Circulating Inflamma-miRs as Potential Biomarkers of Cognitive Impairment in Patients Affected by Alzheimer's Disease

Alzheimer's disease (AD), the most prevalent neurodegenerative disease in the growing population of elderly people, is still lacking minimally-invasive circulating biomarkers that could facilitate the diagnosis and the monitoring of disease progression. MicroRNAs (miRNAs) are emerging as tissue...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in aging neuroscience 2021-03, Vol.13, p.647015-647015
Main Authors: Giuliani, Angelica, Gaetani, Simona, Sorgentoni, Giulia, Agarbati, Silvia, Laggetta, Maristella, Matacchione, Giulia, Gobbi, Mirko, Rossi, Tommaso, Galeazzi, Roberta, Piccinini, Gina, Pelliccioni, Giuseppe, Bonfigli, Anna Rita, Procopio, Antonio Domenico, Albertini, Maria Cristina, Sabbatinelli, Jacopo, Olivieri, Fabiola, Fazioli, Francesca
Format: Article
Language:English
Subjects:
Age
Alzheimer's disease
biomarker
Biomarkers
circulating microRNAs
Cognitive ability
Diabetes
Disease
inflamma-miRs
Inflammation
MicroRNAs
miRNA
Neurodegenerative diseases
Neuroscience
Older people
Plasma
Plasma levels
Tumor necrosis factor-TNF
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Alzheimer's disease (AD), the most prevalent neurodegenerative disease in the growing population of elderly people, is still lacking minimally-invasive circulating biomarkers that could facilitate the diagnosis and the monitoring of disease progression. MicroRNAs (miRNAs) are emerging as tissue-specific and/or circulating biomarkers of several age-related diseases, but evidence on AD is still not conclusive. Since a systemic pro-inflammatory status was associated with an increased risk of AD development and progression, we focused our investigation on a subset of miRNAs modulating the inflammatory process, namely inflamma-miRNAs. The expression of inflamma-miR-17-5p, -21-5p, -126-3p, and -146a-5p was analyzed in plasma samples from 116 patients with AD compared with 41 age-matched healthy control (HC) subjects. MiR-17-5p, miR-21-5p, and miR-126-3p plasma levels were significantly increased in AD patients compared to HC. Importantly, a strong inverse relationship was observed between miR-21-5p and miR-126-3p, and the cognitive impairment, assessed by Mini-Mental State Examination (MMSE). Notably, miR-126-3p was able to discriminate between mild and severe cognitive impairment. Overall, our results reinforce the hypothesis that circulating inflamma-miRNAs could be assessed as minimally invasive tools associated with the development and progression of cognitive impairment in AD.
ISSN:1663-4365
1663-4365
DOI:10.3389/fnagi.2021.647015